Introduction {#s1}
============

Percutaneous coronary intervention (PCI) with stent implantation is the most widely used treatment strategy for coronary artery disease (CAD). Moreover, current generation drug-eluting coronary stents (DES) have remarkable features to improve the clinical outcomes of PCI \[[@R01]\]. However, treatment of long diffused lesions is still a challenge for interventional cardiologists, especially in tapered coronary arteries where the vessel diameter discrepancies may warrant using more than one stent for a long lesion.

Taper is defined as the ratio of the area change to the vessel length. Positive taper refers to a narrowing in cross-section while negative taper refers to an expansion in luminal area \[[@R02]\]. A study by Zubaid et al investigated the magnitude of angiographic tapering in 13 men and 13 women with normal coronary arteries by estimating tapering index (i.e., a difference between the proximal and distal segment diameter, divided by the proximal segment diameter). It was found that proximal and distal left anterior descending artery taper by 18.14% and 29.9% respectively, while the proximal and distal right coronary artery taper by 9.12% and 7.8% respectively, in both men and women \[[@R03]\].

The strategies adopted for treatment of long diffused lesions in tapered arteries include the use of either multiple stents or a single long stent, both of which are associated with clinical failure due to the potential risk of mechanical mismatch of stent size \[[@R01], [@R04], [@R05]\]. Multiple short stents with variable diameters are often implanted (overlapping) to match the size of the long-tapered lesions adequately. However, this solution comes with its own set of limitations, including stent fracture due to vessel rigidity, restenosis because of higher vascular injury, delayed healing, very late stent thrombosis (ST), vessel aneurysm, side branch jailing, increased treatment cost, overuse of anti-restenosis drug and increased exposure to radiation and contrast media \[[@R06]\]. Moreover, implantation of more than one stent might not be necessary or can be completely avoided \[[@R07]\]. Apart from undesirable short-term outcomes, it has been reported that overlapping stents are associated with adverse long-term clinical outcomes, including death or myocardial infarction (MI) \[[@R08]\].

The BioMime™ Morph (Meril Life Sciences Pvt. Ltd., India), a novel long-tapered biodegradable polymer coated sirolimus-eluting coronary stent (SES) system, has been developed to address the aforementioned issues with conventional stents. A single long-tapered BioMime Morph SES system is often enough for treating long diffused lesion in tapered arteries, and therefore, the local arterial walls can be saved from over-exposure to drug/metal and its related adverse events such as delayed healing, peri-procedural MI, risk of target lesion revascularization and very late ST, which are caused due to use of multiple stents. The purpose of this study was to evaluate the safety and performance of long-tapered BioMime Morph SES system in consecutive real-world patients with long diffused *de novo* coronary lesions.

Materials and Methods {#s2}
=====================

Study design and population {#s2a}
---------------------------

This was a retrospective, non-randomized, multicentre study. The study included a total of 362 consecutive patients (aged ≥ 18 years), between November 2014 and June 2017 at five clinical centers across India. All the included consecutive patients had undergone the treatment of long diffuse *de novo* coronary lesion by implantation of at least one long-tapered BioMime Morph SES system. The study was conducted in accordance with the privacy policy of each investigational site, which included their rules and regulations for appropriate use of data in patient-oriented research. This study was in accordance with the Declaration of Helsinki and was approved by the ethics committee. Relevant informed consents were obtained for all the participants prior to the procedure.

Study device and procedure {#s2b}
--------------------------

The BioMime Morph ([Fig. 1](#F1){ref-type="fig"}) is a novel long-tapered biodegradable polymer coated SES system for the treatment of long diffused coronary lesions. It uses an ultra-thin strut (65 µm), cobalt-chromium platform having a unique hybrid design of open and closed cells with uniformly thin coating (2 µm) of bioabsorbable polymers *viz*. PLLA (poly-L-lactic acid) and PLGA (poly-lactic-co-glycolic acid). The stent elutes sirolimus (1.25 µg/mm^2^) within 30 - 40 days after the implantation. Currently available lengths of the BioMime Morph are 30 mm, 40 mm, 50 mm and 60 mm. The stent inflation is guided by the tapered balloon and is estimated to achieve the diameters (proximal to distal) of 2.75 - 2.25 mm, 3.0 - 2.50 mm, 3.50 - 2.75 mm, and 3.50 - 3.0 mm. The device is "Conformite Europeene" (CE) marked.

![Structure and design of long-tapered BioMime™ Morph SES system.](cr-09-350-g001){#F1}

PCI was performed according to the standard treatment guidelines followed by each participating center \[[@R9]\]. Pre-dilatation and post-dilatation were carried out as per the operator's discretion. Before the procedure, a loading dose of aspirin (300 mg) and of a second anti-platelet agent (clopidogrel, ticagrelor, or prasugrel, according to the clinical settings and operator's preference) were administered in all included consecutive patients. Post-procedure, all patients were recommended for dual antiplatelet therapy for at least 12 months, and aspirin (75 - 100mg once daily) indefinitely beyond the first year. Clinical follow-up was performed at 1 month and the clinical/telephonic follow-up was performed at 6 and 12-month after the index procedure and as when needed based on symptoms.

Endpoints and definitions {#s2c}
-------------------------

The safety endpoints were the occurrence of major adverse cardiac events (MACE) at 6 and 12-month follow-up after the index procedure. MACE was defined as the composite of cardiac death, MI attributed to the target vessel, and ischemia-driven target lesion revascularization (ID-TLR). MI was defined as development of new pathological Q waves on electrocardiogram, or elevation of creatinine kinase (CK) ≥ 2 fold the upper limit of normal with elevated CK-MB in the absence of new pathological Q waves or new ischemic symptoms (e.g., chest pain or shortness of breath) \[[@R10]\]. Cardiac death was defined as any death resulting from an acute MI, sudden cardiac death, death due to heart failure or death due to stroke. ID-TLR was defined as any repeat PCI of the target lesion or coronary artery bypass grafting for the lesion in the previously treated segment or within the 5 mm proximal or distal to the stent site or edge of DES inflation. ST was classified according to the definitions of the Academic Research Consortium \[[@R11]\]. Procedural success was defined as a successful PCI without in-hospital major clinical complications which included death, MI, and ID-TLR. Device success was defined as the deployment of the study stent at the intended target lesion with the attainment of final residual stenosis of \< 30% of the target lesion estimated by angiography or by visual estimation.

Statistical analysis {#s2d}
--------------------

Categorical data were presented as frequency and percentages. Continuous variables were presented as mean ± standard deviation. All data were analyzed using the Statistical Package for Social Sciences, version 20 (SPSS, Chicago, IL, USA). The survival probabilities were calculated using the Kaplan-Meier method.

Results {#s3}
=======

Baseline demographic and clinical characteristics {#s3a}
-------------------------------------------------

The data of 362 consecutive patients who were implanted BioMime Morph, were collected in the study, which included majority of males (290; 80.1%). Mean age of patients was 61.09 ± 9.04 years. Diabetes mellitus and hypertension were present in 170 (47.0%) and 159 (43.9%) patients, respectively which are conventional risk factors for CAD. Majority of patients (110; 30.4%) presented with refractory stable angina. Baseline demographics and clinical characteristics of patients are shown in [Table 1](#T1){ref-type="table"}.

###### Baseline Demographics and Clinical Characteristics

  Characteristics                                    Patients (n = 362)
  -------------------------------------------------- --------------------
  Patient demographics                               
    Age (mean ± SD), years                           61.09 ± 9.04
    Male                                             290 (80.1)
  Baseline medical history                           
    Diabetes mellitus                                170 (47.0)
    Hypertension                                     159 (43.9)
    Smoker                                           15 (4.1)
    Previous CABG                                    5 (1.4)
    Previous PCI                                     22 (6.1)
    History of angina                                124 (34.3)
    Family history of CAD                            55 (15.2)
    Previous stroke                                  8 (2.2)
    Previous chronic obstructive pulmonary disease   6 (1.7)
    Previous MI                                      43 (11.9)
  Cardiac status before index procedure              
    Stable angina                                    110 (30.4)
    Unstable angina                                  50 (13.8)
    STEMI                                            69 (19.1)
    NSTEMI                                           44 (12.2)
    Asymptomatic                                     89 (24.6)
  LVEF %, mean ± SD                                  46.96 ± 10.02

CABG: coronary artery bypass grafting; CAD: coronary artery disease; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NSTEMI: non ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction. Values are presented as frequency (percentage).

Lesion and procedural characteristics {#s3b}
-------------------------------------

Lesion and procedural characteristics are illustrated in [Table 2](#T2){ref-type="table"}. A total of 625 lesions were identified in 362 consecutive patients. Out of which, 402 long diffused *de novo* type C coronary lesions (1.11 lesions per patient) with average lesion length of 40.25 ± 5.54 mm were successfully intervened with 390 BioMime Morph novel long-tapered SES system, 144 lesions were treated with 132 other stents, and 79 lesions were not treated with stents ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). Majority of stents were implanted in the left anterior descending artery (236; 58.7%) followed by in right coronary artery (128; 31.8%), left circumflex artery (33; 8.2%), and left main coronary artery (5; 1.2%). The average length of the implanted BioMime Morph was 44.85 ± 10.23 mm along with average diameters of 3.2 ± 0.29 mm (proximal) and 2.70 ± 0.29 mm (distal). Immediate procedural and device success rate was 99.7% and 100%, respectively.

###### Lesion and Procedural Characteristics

  Characteristics                                                 Patients (n = 362)/lesions (n = 625)
  --------------------------------------------------------------- --------------------------------------
  Total number of lesions treated with BioMime Morph SES system   402
  Total number of lesions treated with other stents               144
  Unknown/ no stent treated lesions                               79
  Target lesion location                                          
    Left anterior descending artery                               236/402 (58.7)
    Right coronary artery                                         128/402 (31.8)
    Left circumflex artery                                        33/402 (8.2)
    Left main                                                     5/402 (1.2)
    Lesion per patient                                            1.11 (402/362)
  Disease vessel                                                  
    Single vessel disease                                         156/362 (43.1)
    Double vessel disease                                         125/362 (34.5)
    Triple vessel disease                                         81/362 (22.4)
  Average target lesion length (mm), Mean±SD                      40.25 ± 5.54
  \% Occlusion, Mean±SD                                           86.10 ± 9.50

Values are presented as frequency (percentage).

###### BioMime Morph SES system characteristics

  Characteristics                                     Patients (n=362)
  --------------------------------------------------- ------------------
  Stent length (mm)                                   
    30                                                77/390 (19.74)
    40                                                125/390 (32.05)
    50                                                110/390 (28.21)
    60                                                78/390 (20.00)
    Average stent length (mm), mean ± SD              44.85 ± 10.23
  Stent diameter (mm)                                 
    2.75 - 2.25                                       53/390 (13.59)
    3.00 - 2.50                                       151/390 (38.72)
    3.5 - 2.75                                        15/390 (3.85)
    3.5 - 3.0                                         171/390 (43.85)
    Average proximal stent diameter (mm), mean ± SD   3.2 ± 0.29
    Average distal stent diameter (mm), mean ± SD     2.70 ± 0.29
  BioMime Morph SES system per patient                1.08 (390/362)

Values are presented as frequency (percentage).

###### Other Implanted Stent Characteristics

  Characteristics                                     Patients (n = 362)
  --------------------------------------------------- --------------------
  Total number of lesions treated with other stents   144
  Total number other stents implanted                 132
  Average stent length (mm), mean ± SD                22.97 ± 9.03
  Average stent diameter (mm), mean ± SD              2.95 ± 0.38
  Other stent used                                    
    Metafor                                           1/132 (0.76)
    Ultimaster                                        1/132 (0.76)
    Resolute integrity                                1/132 (0.76)
    Promus PREMIER                                    1/132 (0.76)
    GRAFTMASTER RX                                    2/132 (1.52)
    Resolute onyx                                     2/132 (1.52)
    Endeavour                                         3/132 (2.27)
    Endeavour resolute                                3/132 (2.27)
    Xience family                                     8/132 (6.06)
    BioMime Aura                                      13/132 (6.85)
    PROMUS Element                                    12/132 (9.09)
    Evermine 50                                       37/132 (28.03)
    BioMime                                           48/132 (36.36)
  No stent treated lesions                            79

Values are presented as frequency (percentage).

Clinical outcomes at follow-up {#s3c}
------------------------------

Clinical follow-up was completed in 98.1% of included patients at 6 and 12-month ([Table 5](#T5){ref-type="table"}). Out of 362 patients, seven (1.9%) were lost to follow-up ([Fig. 2](#F2){ref-type="fig"}). Cumulative incidence of MACE at 6 and 12-month was four (1.1%) and seven (2.0%), respectively. There were four (1.1%) cardiac deaths, one (0.3%) MI and two (0.6%) ID-TLRs at 12-month follow-up. The Kaplan-Meier method and survival rate performed time-to-event analysis of 12-month was found to be 98.0% ([Fig. 3](#F3){ref-type="fig"}). There was a single (0.3%) incidence of acute ST immediately after the index procedure and was attributed to resistance to clopidogrel as documented by platelet aggregometry later on. The patient was immediately treated with plain only balloon angioplasty and was stabilized, and discharged 3 days later.

###### Cumulative Major Adverse Events at 1, 6 and 12-Month Follow-Up

  Events                In-hospital, n (%)   1-month, n (%)   6-month, n (%)   12-month, n (%)
  --------------------- -------------------- ---------------- ---------------- -----------------
  All cause death       0 (0.0)              2 (0.6)          4 (1.1)          6 (1.7)
    Cardiac death       0 (0.0)              1 (0.3)          2 (0.6)          4 (1.1)
    Non-cardiac death   0 (0.0)              1 (0.3)          2 (0.6)          2 (0.6)
  MI                    0 (0.0)              1 (0.3)          1 (0.3)          1 (0.3)
  ID-TLR                0 (0.0)              0 (0.0)          1 (0.3)          2 (0.6)
  ST                    1 (0.3)              1 (0.3)          1 (0.3)          1 (0.3)
    Acute               1 (0.3)              1 (0.3)          1 (0.3)          1 (0.3)
    Sub-acute           0 (0.0)              0 (0.0)          0 (0.0)          0 (0.0)
    Late                0 (0.0)              0 (0.0)          0 (0.0)          0 (0.0)
  MACE                  0 (0.0)              2 (0.6)          4 (1.1)          7 (2.0)

n: number of patients; MI: myocardial infarction; ID-TLR: ischemia-driven target lesion revascularization; ID-TVR: ischemia driven target vessel revascularization; MACE: major adverse cardiac events; ST: stent thrombosis. Values are presented as frequency (percentage).

![Patients follow-up details at 1 and 12-month.](cr-09-350-g002){#F2}

![Time-to-event curve by Kaplan-Meier method at 12-month follow-up.](cr-09-350-g003){#F3}

Discussion {#s4}
==========

In the current study, long-tapered BioMime Morph SES system has demonstrated safety and performance in consecutive real-world patients with long diffused *de novo* coronary lesions. In addition to the high (99.7%) procedural and (100%) device success, the cumulative MACE rate was four (1.1%) and seven (2.0%) at 6 and 12-month follow-up, respectively and there was one (0.3%) case of acute ST immediately after the procedure.

Studies have shown that the dimensions of coronary arteries taper naturally along with their length. In one study, Banka et al analyzed tapered coronary anatomy, 1 cm proximal and distal to the stenosis, in 100 consecutive coronary arteries. They observed that 23% of arteries had ≥ 1 mm taper and 19% arteries had a 0.5 - 0.99 mm taper \[[@R12]\]. Hence, stent sizing is critical for the success of PCI for treating long-tapered lesions as "stent over-sizing" (stent larger in diameter than the healthy artery) may induce pathological stress on the arterial wall and damage to the artery may be irreversible leading to aneurysm formation, late ST and even late perforations. This may also lead to accelerated vascular injury and augmented neointima formation, leading to in-stent restenosis; whereas "stent under-sizing" (stent smaller in diameter than the healthy artery) may lead to ST as a consequence of stent malposition \[[@R13]\]. In light of these, tapered stents have been developed to minimize clinical failure and maximize the clinical benefits in such patients. The long-tapered BioMime Morph SES system comes with a tapered balloon and is designed to undergo "morphology-mediated" expansion and therefore prevents artery dissection or over-inflation at the distal end of the lesion. In fact, few case studies have reported that using long-tapered stent offers the advantage of favorable adaptation to vessel tapering, vessel size, and good apposition in patients with long-tapered coronary lesions along with good coronary flow \[[@R14], [@R15]\].

Valero et al assessed safety and efficacy of the BioMime Morph in prospective clinical cohort study which included 50 consecutive patients in whom the implantation of a 60 mm long DES was attempted due to the presence of coronary lesions longer than 48 mm (78% coronary lesions longer than 48 mm and 22% multiple severe tandem lesions involving arterial segments longer than 48 mm) on angiography. The authors reported optimal angiographic result in 46 (92%) patients despite unfavorable anatomy. There was no angiographic distal vessel dissection which can be explained by the tapered design of the stent. Moreover, all the procedures were performed with an acceptable mean fluoroscopy time (17 ± 9 min) and mean contrast volume (168 ± 49 mL per procedure) when compared to other series reported in the treatment of long coronary lesions \[[@R16]\]. Zivelonghi et al demonstrated safety and feasibility of the long-tapered BioMime Morph SES system for treatment of the long lesion with chronic total occlusion. The authors noted a high device success rate (only one failure) with the low incidence of peri-procedural complications (one dissection; one perforation leading to pericardial hematoma and one peri-procedural MI) and promising short-term clinical outcomes for BioMime Morph at a mean follow-up of 10 months \[[@R17]\]. In addition, satisfactory clinical outcomes (9.4% MACE with no ST at 12-month clinical follow-up) with the use of very long-tapered BioMime stent (60 mm) were reported by Matchin et al \[[@R18]\]. Also, Qiao Shu Bin et al assessed the cumulative incidence of MACE (death, acute MI, and target-vessel revascularization) and ST in a total of 2,371 patients who underwent single stenting (n = 1,233) and multiple stenting (n = 1,138). The 6-month cumulative incidence of MACE was 4.9% in the multiple stenting group and 3.2% in the single stenting group (P = 0.04). A non-significant difference was also detected in favor of the single stenting group, as compared with the multiple stenting group, at the rate of ST (0.5% vs. 0.8%, P = 0.35) \[[@R07]\]. The outcomes (2.0% MACE, and a single incident of acute ST) of the present study at 12-month follow-up are consistent with these previous studies.

The limitations of this study include 12-month follow-up period, which may not be enough for the determination of long-term safety and performance of long-tapered BioMime Morph SES system in patients with long diffused *de novo* coronary lesions. Moreover, this was a retrospective, non-randomized, multicentric study and consequently, further large prospective studies with long-term follow-up are necessary. This study lacks angiographic data, and hence, we could not identify any possible complications like stent fracture at the deployment site nor the angiographic characteristics of restenosis with long-tapered coronary stent system.

Conclusions {#s4a}
-----------

The present study demonstrated favourable procedural success and device success in addition to optimum safety outcomes with the use of long-tapered BioMime Morph SES system in a real-world pateints with long diffused *de novo* coronary lesions.
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